NCT06993181View on ClinicalTrials.gov

Clinical Trial of Comparing DA-5222 Single-administration and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in Healthy Adult Subjects

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions
Healthy
Interventions
DRUG

DA-5222

single dose administration (DA-5222 one tablet once a day)

DRUG

DA-5222-R1

single dose administration (DA-5222-R1 one tablet once a day)

DRUG

DA-5222-R2

single dose administration (DA-5222-R2 one tablet once a day)

DRUG

DA-5222-R3

single dose administration (DA-5222-R3 one tablet once a day)

Trial Locations (1)

07590

Bumin Hospital, Seoul

All Listed Sponsors
lead

Dong-A ST Co., Ltd.

INDUSTRY